Antigen fragment and truncation based on ebola virus envelope protein as well as application

A protein and short body technology, applied in the direction of viral antigen components, antiviral immunoglobulin, virus/bacteriophage, etc., to achieve good immunogenicity, infection inhibition, and good safety effects

Active Publication Date: 2014-06-18
INST OF BIOENG ACAD OF MILITARY MEDICAL SCI OF THE CHINESE
View PDF3 Cites 29 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, there are no effective vaccines and drugs fo

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antigen fragment and truncation based on ebola virus envelope protein as well as application
  • Antigen fragment and truncation based on ebola virus envelope protein as well as application
  • Antigen fragment and truncation based on ebola virus envelope protein as well as application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] Embodiment 1, the immunogenicity analysis of antigen and fragment thereof

[0061] 1. Construction of recombinant plasmids

[0062] Simultaneously construct pVAX1-GP, pVAX1-L recombinant plasmids and L truncated LA, LB, LM recombinant plasmids pVAX1-LA, pVAX1-LM and pVAX1-LB.

[0063] Specific steps are as follows:

[0064] (1) Design and synthesize the following primers:

[0065] GPF: 5'-GAATTCGCCACCATGGGTGTTACAGGAATATTG-3'

[0066] GPR: 5'-CCGCTCGAGTTAAAAGACAAATTTGCATAT-3'

[0067] LF / LAF:5'-GAATTCGCCACCATGGTGTATAAACTTGACATCTCTG-3'

[0068] LR / LBR:5'-CCGCTCGAGTTAACAGATTAAACCATCTTG-3'

[0069] LAR:5'-CCGCTCGAGTTATAGCTTCCCGCTGCTGGC-3'

[0070] LMF: 5'-GGAATTCGCCACCATGAACACGAGCAAGGGTAC-3'

[0071] LMR: 5'-CCGCTCGAGTTAAGTCCAGTAATGTAAATT-3'

[0072] LBF: 5'-GGAATTCGCCACCATGGGCTTAATTACCAATACT-3'

[0073] (2) GP gene amplification

[0074] Using pCAGGS-GP as a template and using GPF and GPR as primers to perform PCR amplification, the PCR amplification product 1 wa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an antigen fragment and truncation based on ebola virus envelope protein as well as an application. The protein or the truncation of the protein is disclosed by the invention; the protein is shown in SEQ ID No. 3 or protein which is obtained by replacing and/or deleting and/or adding one or more amino acid residues in an amino acid sequence shown in the SEQ ID No. 3 and has the identical function as the protein shown in SEQ ID No. 3. The antigen fragment and the truncation thereof disclosed by the invention can induce relatively strong humoral immune response, has good immunogenicity and can be applied to development of ebola virus vaccines and preparation of neutralizing antibodies.

Description

technical field [0001] The invention relates to an antigen fragment, a truncated body and application based on the envelope protein of Ebola virus. Background technique [0002] Ebola virus (EBOV) is the causative agent of Ebola hemorrhagic fever (EHF), a severe infectious disease. (ZEBOV), Sudan Ebola (SEBOV), Cote d'Ivoire Ebola (CIEBOV), Bundibugyo Ebola (BEBOV) and Reston Ebola (REBOV) (Kuhn, JH, Becker et al. Arch. Virol, 2010, 155, 2083–2103 ). Since the first discovery of Ebola virus in 1976, outbreaks of EHF have caused a large number of deaths, with a mortality rate approaching 90%. After Ebola virus infection, related disease symptoms appear soon, including headache, myalgia, fever, multiple organ failure and shock (Ksiazek TG et al. J Dis1999;179(Suppl1):S177–S187). Currently, there are no effective vaccines and drugs for the prevention and treatment of Ebola virus infection. [0003] The full-length Ebola virus genome is 19kb, encoding 7 proteins, including 4...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/08C12N15/40C07K16/10A61K39/12A61P31/14
CPCA61K39/00C07K14/005C12N2760/14122C12N2760/14134
Inventor 戴秋云王于刘珠果张科军朱翠余硕
Owner INST OF BIOENG ACAD OF MILITARY MEDICAL SCI OF THE CHINESE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap